SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs1061325

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 The Role of Genetic Variation in CLTCL1 and Other Related Genes in Relation to Whole-body Glucose Control: A Pilot Study

Maintaining stable blood glucose concentrations after eating has important implications for health. Individuals who are better able to maintain stable blood glucose concentrations after consuming carbohydrate have a lower risk of mortality from cardiovascular disease. Muscle is the primary tissue for glucose disposal following a meal, and responsiveness of this tissue to insulin is dictated by GLUT4 translocation to the muscle cell membrane. Clathrin heavy chain isoform 22 (CHC22) is a protein that plays a key role in intracellular GLUT4 action, and it may play an important role in whole-body glucose control. Genetic variation in the gene which codes for CHC22 may be able to explain differences in glucose control at the whole-body level.

NCT03998111 Glucose Control Diagnostic Test: Oral glucose tolerance test

Cell-based studies suggest that genetic variation in the CLTCL1 gene (which encodes for CHC22) at SNP rs1061325, influences GLUT4 retention.

Primary Outcomes

Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the incremental area under the curve will be calculated, this will be grouped by CHC22 genotype.

Measure: Plasma glucose incremental area under the curve (CHC22 genotype)

Time: 2 hours

Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the peak glucose concentration will be measured, this will be grouped by CHC22 genotype.

Measure: Peak plasma glucose (CHC22 genotype)

Time: 2 hours

Secondary Outcomes

Description: Plasma glucose will be measured at baseline and will be grouped by CHC22 genotype.

Measure: Fasting plasma glucose concentrations (CHC22 genotype)

Time: 2 hours

Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the incremental area under the curve will be calculated, this will be grouped by genotyping other genes related to glucose control or sweet taste sensitivity.

Measure: Plasma glucose incremental area under the curve (other genotypes)

Time: 2 hours

Description: Plasma glucose will be measured at baseline and will be grouped by genotypes related to glucose control and sweet taste sensitivity.

Measure: Fasting plasma glucose concentrations (other genotypes)

Time: 2 hours

Description: Matsuda insulin sensitivity index will be calculated using blood samples collected in the 2-hour postprandial period.

Measure: Matsuda insulin sensitivity index

Time: 2 hours

Description: Homeostasis model of insulin resistance will be calculated using blood samples collected in the 2-hour postprandial period.

Measure: Homeostasis model of insulin resistance

Time: 2 hours


HPO Nodes